Karyopharm Therapeutics KPTI Stock
Karyopharm Therapeutics Price Chart
Karyopharm Therapeutics KPTI Financial and Trading Overview
| Karyopharm Therapeutics stock price | 9 USD |
| Previous Close | 9.1 USD |
| Open | 9.15 USD |
| Bid | 8.45 USD x 100 |
| Ask | 11.26 USD x 100 |
| Day's Range | 8.99 - 9.88 USD |
| 52 Week Range | 3.65 - 10.99 USD |
| Volume | 330.03K USD |
| Avg. Volume | 919.36K USD |
| Market Cap | 222.55M USD |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -16.4 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.5 USD |
KPTI Valuation Measures
| Enterprise Value | 411.03M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.00818 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.4726908 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 2.72 |
| Enterprise Value/EBITDA | -4.898 |
Trading Information
Karyopharm Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.81 |
| 52-Week Change | 120.87% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 10.99 USD |
| 52 Week Low | 3.65 USD |
| 50-Day Moving Average | 7.94 USD |
| 200-Day Moving Average | 7.08 USD |
KPTI Share Statistics
| Avg. Volume (3 month) | 919.36K USD |
| Avg. Daily Volume (10-Days) | 511.73K USD |
| Shares Outstanding | 22.66M |
| Float | 14.7M |
| Short Ratio | 12.69 |
| % Held by Insiders | 4.68% |
| % Held by Institutions | 83.46% |
| Shares Short | 5.28M |
| Short % of Float | 23.40% |
| Short % of Shares Outstanding | 23.28% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -129.018% |
| Operating Margin (ttm) | -76.31% |
| Gross Margin | 13.45% |
| EBITDA Margin | -55.53% |
Management Effectiveness
| Return on Assets (ttm) | -40.62% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 151.12M USD |
| Revenue Per Share (ttm) | 10.55 USD |
| Quarterly Revenue Growth (yoy) | 16.80% |
| Gross Profit (ttm) | 20.33M USD |
| EBITDA | -83919000 USD |
| Net Income Avi to Common (ttm) | -194968992 USD |
| Diluted EPS (ttm) | -16.4 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 90.85M USD |
| Total Cash Per Share (mrq) | 4.03 USD |
| Total Debt (mrq) | 296.73M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | N/A |
| Book Value Per Share (mrq) | -11.783 |
Cash Flow Statement
| Operating Cash Flow (ttm) | N/A |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Karyopharm Therapeutics
| Country | United States |
| State | MA |
| City | Newton |
| Address | 85 Wells Avenue |
| ZIP | 02459-3298 |
| Phone | 617 658 0600 |
| Website | https://www.karyopharm.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 228 |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Q&A For Karyopharm Therapeutics Stock
What is a current KPTI stock price?
Karyopharm Therapeutics KPTI stock price today per share is 9 USD.
How to purchase Karyopharm Therapeutics stock?
You can buy KPTI shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Karyopharm Therapeutics?
The stock symbol or ticker of Karyopharm Therapeutics is KPTI.
Which industry does the Karyopharm Therapeutics company belong to?
The Karyopharm Therapeutics industry is Biotechnology.
How many shares does Karyopharm Therapeutics have in circulation?
The max supply of Karyopharm Therapeutics shares is 22.66M.
What is Karyopharm Therapeutics Price to Earnings Ratio (PE Ratio)?
Karyopharm Therapeutics PE Ratio is now.
What was Karyopharm Therapeutics earnings per share over the trailing 12 months (TTM)?
Karyopharm Therapeutics EPS is -16.4 USD over the trailing 12 months.
Which sector does the Karyopharm Therapeutics company belong to?
The Karyopharm Therapeutics sector is Healthcare.
Karyopharm Therapeutics KPTI included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Biotechnology Total Retu XNBI | 6334.93 USD — |
+1.87
|
— — | 6201.97 USD — | 6337.77 USD — | — - | — — |
| US Tech Global Select Market Com NQGS | 13180.97 USD — |
-0.87
|
— — | 13139.79 USD — | 13316.81 USD — | — - | — — |
| US Tech Biotechnology NBI | 5807.22 USD — |
+1.87
|
— — | 5685.34 USD — | 5809.82 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
| US Tech Composite Total Return XCMP | 33104.2 USD — |
-0.89
|
— — | 32999.64 USD — | 33445.55 USD — | — - | — — |
| Stlmt ID US Tech Biotechnology NBX | 3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}